CarmeloAnthonyPuccioMD

PubMed

• 24 citations
  Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors
  Jibran Ahmed, Arun Kumar, Kaushal Parikh, Asad Anwar, Bettina M. Knoll, C. Puccio, Hoo Chun, Michael Fanucchi, Seah H. Lim> ;OncoImmunology. 2018 Aug 20
• 7 citations
  Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer.
  Kaushal Parikh, Arun Kumar, Jibran Ahmed, Asad Anwar, C. Puccio, Hoo Chun, Michael Fanucchi, Seah H. Lim> ;Cancer Immunology, Immunotherapy. 2018 Jul 2
• High-dose therapy with autologous stem cell rescue in patients with breast cancer at high risk for relapse.
  Farjami S, Kancherla R, Qureshi Z, Hoang A, Puccio C, Mittelman A, Seiter K, Ahmed T> ;J. Clin. Oncol.. 2005-06-01
• TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
  Razis ED, Samonis G, Cook P, Beer M, Mittelman A, Lake DE, Feldman EJ, Puccio C, Ahmed T> ;J Med. 1994-01-01
• Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.
  Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, Chun HG, Helson L, Mittelman A> ;Acta Haematol.. 1994-01-01
• Improving the "quality of remission induction" therapy: a necessary step for increasing the cure rate in acute myelogenous leukemia.
  Arlin ZA, Feldman E, Finger L, Decter J, Cook P, Ahmed T, Puccio C, Chun H, Mittelman A> ;Cancer Invest.. 1992-01-01
• Amsacrine retains a special role supporting Food and Drug Administration approval.
  Arlin ZA, Feldman EJ, Cook P, Ahmed T, Mittelman A, Chun HG, Puccio C, Helson L> ;J. Clin. Oncol.. 1992-01-01
• Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
  Arlin ZA, Feldman EJ, Mittelman A, Ahmed T, Puccio C, Chun HG, Cook P, Baskind P, Marboe C, Mehta R> ;Cancer. 1991-09-15
• Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
  Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED> ;Leukemia. 1991-08-01
• "Quality" remissions: a new target of induction therapy in acute leukemia and the next step in developing curative treatment.
  Arlin ZA, Feldman EJ, Finger L, Ahmed T, Mittelman A, Puccio C, Cook P, Chun HG> ;Semin. Hematol.. 1991-07-01
• Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.
  Lichtman SM, Mittelman A, Budman DR, Puccio CA, Chun HG, Allen SL, Ahmed T, Arlin ZA> ;Leuk. Lymphoma. 1991-01-01
• Preliminary Experience with Short Course High-Dose Mitoxantrone in Combination with High-Dose Cytarabine in Patients with Acute Leukemia and Blastic Phase of Chronic M...
  Feldman EJ, Biguzzi S, Ahmed T, Mittelman A, Puccio CA, Baskind P, Arlin ZA> ;Leuk. Lymphoma. 1990-01-01
• Amsacrine is safe in patients with ventricular ectopy.
  Puccio CA, Feldman EJ, Arlin ZA> ;Am. J. Hematol.. 1988-07-01
• Pericardial synovial sarcoma: challenges in diagnosis and management.
  Phatak, P.,Khanagavi, J.,Aronow, W. S.,Puri, S.,Yusuf, Y.,Puccio, C.,Phatak, P.,Khanagavi, J.,Aronow, W. S.,Puri, S.,Yusuf, Y.,Puccio, C.> ;F1000Res. 2014 Apr 10
• Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage.
  Feldman, E. J., Arlin, Z. A., Ahmed, T., Mittelman, A., Ascensao, J. L., Puccio, C. A., Coombe, N., Baskind, P.> ;Acta Haematol. 1989
• Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy.
  Arlin, Z. A., Ahmed, T., Mittelman, A., Cook, P., Puccio, C. A., Helson, L., Chun, H. G.> ;Int J Clin Lab Res. 1992
• A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
  Puccio, C. A., Mittelman, A., Lichtman, S. M., Silver, R. T., Budman, D. R., Ahmed, T., Feldman, E. J., Coleman, M., Arnold, P. M., Arlin, Z. A.> ;J Clin Oncol. 1991 Sep
• Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
  Mikulski, S. M., Costanzi, J. J., Vogelzang, N. J., McCachren, S., Taub, R. N., Chun, H., Mittelman, A., Panella, T., Puccio, C., Fine, R., Shogen, K.> ;J Clin Oncol. 2002 Jan 1
• Join now to see all